Key facts
- Boomerang Medical’s last known valuation is $75.0M (Sep 2025).
- It has raised $38.0M; the latest was Early Stage VC ($20.0M) in Sep 2025.
- Notable investors include Hatteras Venture Partners, Arboretum Ventures, Fogarty Innovation.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Boomerang Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Boomerang Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Boomerang Medical
Developer of bioelectronic medicine technology designed to advance the treatment of autoimmune diseases. The company offers to focus on inflammatory bowel disease (IBD) and disrupt the treatment of autoimmune diseases by developing a bioelectric neuromodulation technology, which has been granted breakthrough device designation by the FDA(Food and Drug Administration) for the treatment of Crohn's disease and ulcerative colitis, enabling patients to improve their lives by receiving better treatments.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2021
- Employees
- 9
- Website
- boomerangmedical.com/
- Ownership
- Privately Held (backing)
Boomerang Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Boomerang Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Boomerang Medical in its N-PORT filings yet. We sweep new filings monthly.